BostonGene Tumor Portrait® test
The Tumor Portrait test identifies key biomarkers for response to various therapies in patients with advanced solid tumors, offering the first comprehensive genomic profiling combined with tumor microenvironment (TME) analysis. The test provides personalized treatment options by integrating the results of three NGS assays in a single, streamlined report:
DNA sequencing of tumor FFPE tissue, DNA sequencing of normal sample, RNA sequencing of tumor FFPE tissue.
DNA sequencing of tumor FFPE tissue, DNA sequencing of normal sample, RNA sequencing of tumor FFPE tissue.
.webp)
.webp)
.webp)
.webp)
.webp)
.webp)
.webp)
.webp)
.webp)
Comprehensive tumor profiling
The Tumor Portrait offers a 360° view of the patient's tumor, capturing all clinically actionable findings.
.webp)
99.9%
Accuracy
99.9%
Specificity
19K+
Covered genes
Tailored solutions for each cancer type
BostonGene addresses the unique needs of specialized oncology practices by focusing on clinically relevant biomarkers and molecular findings specific to each cancer type.
Key reported biomarkers include but are not limited to:
DNA
BRCA1/2 germline variants
|
|
DNA
BRCA1/2 somatic mutations
|
|
DNA
PALB2 germline variants
|
|
DNA
ERBB2 alterations
|
|
DNA
TMB-H
|
Key reported biomarkers include but are not limited to:
|
DNA
dMMR/MSI-H
|
|
DNA
KRAS alterations
|
|
DNA
NRAS alterations
|
|
DNA
BRAF alterations
|
|
DNA
ERBB2 amplification
|
Key reported biomarkers include but are not limited to:
|
DNA
ERBB2 amplification
|
|
DNA
dMMR/MSI-H
|
|
DNA
BRAF V600E mutation
|
RNA
NTRK1/2/3 fusions
|
|
RNA
RET fusions
|
Key reported biomarkers include but are not limited to:
|
DNA
BRCA1/2 alterations
|
|
DNA
PALB2 alterations
|
|
DNA
dMMR/MSI-H
|
|
RNA
RET fusions
|
|
RNA
NTRK1/2/3 fusions
|
Key reported biomarkers include but are not limited to:
|
DNA
FGFR3 alterations
|
|
DNA
MSI-H
|
|
DNA
CDKN2A alterations
|
|
DNA
PIK3CA alterations
|
|
DNA
ERBB2 alterations
|
Key reported biomarkers include but are not limited to:
|
DNA
VHL alterations
|
|
DNA
FH germline variants
|
|
DNA
FLCN germline variants
|
|
DNA
MET alterations
|
|
DNA
BAP1 germline variants
|
Key reported biomarkers include but are not limited to:
|
DNA
Germline variants in HRR genes
|
|
DNA
Somatic mutations in HRR genes
|
|
DNA
dMMR/MSI-H
|
|
DNA
AR alterations
|
|
DNA
PTEN alterations
|
Key reported biomarkers include but are not limited to:
|
DNA
EGFR mutations
|
|
DNA
KRAS mutations
|
|
DNA
MET alterations
|
|
DNA
ERBB2 mutations
|
|
RNA
ALK fusions
|
Key reported biomarkers include but are not limited to:
|
DNA
dMMR/MSI-H
|
|
DNA
PIK3CA alterations
|
|
DNA
TMB-H
|
|
DNA
CDKN2A alterations
|
|
RNA
NTRK 1/2/3 fusions
|
Key reported biomarkers include but are not limited to:
|
DNA
BRCA1/2 germline variants
|
|
DNA
BRCA1/2 somatic mutations
|
|
DNA
dMMR/MSI-H
|
|
DNA
BRAF V600E mutation
|
|
RNA
NTRK1/2/3 fusions
|
Key reported biomarkers include but are not limited to:
|
DNA
BRAF alterations
|
|
DNA
KIT alterations
|
|
DNA
NRAS alterations
|
|
RNA
ROS1 fusions
|
|
RNA
NTRK1/2/3 fusions
|
Key reported biomarkers include but are not limited to:
|
DNA
dMMR/MSI-H
|
|
DNA
PDGFRA mutations
|
|
RNA
NTRK1/2/3 fusions
|
|
RNA
RET fusions
|
|
RNA
Novel fusions
|
Key reported biomarkers include but are not limited to:
|
DNA
EZH2 mutations
|
|
DNA
STAT6 mutations
|
|
DNA
TNFRSF14 alterations
|
Key reported biomarkers include but are not limited to:
|
DNA
Genetic subtypes
|
|
RNA
Cell of Origin Subtype
|
|
RNA
CD30 expression
|
|
RNA
DHITsig+/-
|
|
RNA
ALK fusions
|
All key findings and recommendations on one page
A simple, streamlined report summary for informed clinical decision
.webp)
.webp)
.webp)
.webp)
.webp)
The power of TME reconstruction
By analyzing TME characteristics using RNA-seq signatures, BostonGene has identified four distinct TME types that help predict cancer prognosis. When combined with TMB status, these TME types provide critical insights for optimizing immunotherapy strategies.
Patient-centered treatment recommendations
BostonGene’s treatment selection algorithms integrate a patient’s clinical history, molecular profile, FDA-approved therapies and the latest scientific research to provide personalized therapy recommendations.
Clinical trials matching
Our AI-powered clinical trial recommendation tool optimizes trial selection by aligning a patient’s clinical and molecular data with trial eligibility criteria.
.webp)
Clinical trial database
- Daily database updates
- Integrates ClinicalTrials.gov data
- Annotates sponsor and clinic websites
.webp)
Initial filtration
- Country
- Gender
- Age
- Diagnosis
- Clinical parameters
- Additional parameters
.webp)
Personalized selection
- Molecular findings
- Location (trials at patient’s hospital are prioritized)
- Study characteristics
- Trial sponsor
- Additional parameters
How to start
01
Request a test kit
Contact your BostonGene representative or email [email protected] to request test kits.
02
Submit documentation
Complete the Test Requisition Form (TRF) and submit it along with accompanying documents (such as progress notes and pathology reports) to BostonGene.
03
Collect normal sample
Use the provided test kit to collect and send the normal sample (blood, saliva or buccal swab) to BostonGene.
04
Provide tumor sample
BostonGene will retrieve the tumor sample from pathology. All analyses are conducted in BostonGene's CAP/CLIA-certified laboratory.
05
Retrieve results
Test results will be available via the customer portal. You will receive an email with a portal activation link once your first report is ready.
.webp)
.webp)
.webp)
.webp)
.webp)
Helpful resources
